Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,043 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Recruiting Phase 4 Interventional Accepts healthy volunteers

Durability of Vaccine Responses

NCT05801978
Conditions
Vaccine Response
Interventions
Live Attenuated Yellow Fever 17D Vaccine, Quadrivalent seasonal influenza vaccine
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Conditions
Postoperative Pain, Acute, Shoulder Pain
Interventions
intercostobrachial nerve block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Treatment of Facial Flushing With Botulinum Toxin A Injections

NCT02216838
Conditions
Facial Flushing
Interventions
botulinum toxin A, Saline Control
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

NCT03379168
Conditions
Knee Osteoarthritis
Interventions
Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline
Device · Drug
Lead sponsor
Dustin L. Richter, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV-B, Engerix-B, Placebo
Biological · Other
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Terminated Phase 2 Interventional Results available

Pegylated Interferon Lambda Treatment for COVID-19

NCT04343976
Conditions
COVID-19, COVID
Interventions
Pegylated interferon lambda
Drug
Lead sponsor
Raymond Chung
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HIV Infections
Interventions
env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hernia, Ventral, Pain Management
Interventions
Quadratus Lumborum (QL) Block, Placebo
Procedure
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Hypertension, End Stage Renal Disease
Interventions
Vasopressin - Very Low Dose, Vasopressin - Low Dose, Placebo Comparator
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Conditions
Endoscopic Ultrasound (EUS), Endoscopic Retrograde Cholangiopancreatography (ERCP)
Interventions
Meperidine, Midazolam, Diphenhydramine, Promethazine
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Orange, California
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Restylane Silk for Treatment of Chest Wrinkles

NCT03324997
Conditions
Wrinkle
Interventions
Restylane Silk, Saline, Optical Coherence Tomography
Drug · Device
Lead sponsor
Heidi Waldorf
Other
Eligibility
25 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Conditions
Non-healing Wound
Interventions
CeFAZolin Injectable Solution
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Elevated Lipoprotein(a), Cardiovascular Disease
Interventions
ISIS 681257, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Cottonwood, Arizona • Huntington Beach, California • La Jolla, California + 18 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

NCT03524118
Conditions
Respiratory Tract Infection, Respiratory Syncytial Virus
Interventions
Clesrovimab, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Weeks to 8 Months
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
17
States / cities
Aurora, Colorado • Homestead, Florida • Miami, Florida + 14 more
Conditions
Wound; Abdomen, Abdominal Wall
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • Saint Paul, Minnesota
Conditions
Nasal Polyps
Interventions
Depemokimab (GSK3511294), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Tucson, Arizona • Roseville, California • New Haven, Connecticut + 11 more
Conditions
Diabetes, Hyperglycemia, Surgical Site Infection
Interventions
Tight Glycemic, Conventional Glycemic, Standard Glycemic
Drug
Lead sponsor
James A. Haley Veterans Administration Hospital
Federal
Eligibility
21 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Terminated Phase 2Phase 3 Interventional Results available

Controlling Rapid Atrial Fibrillation With Dexmedetomidine

NCT04042727
Conditions
Rapid Atrial Fibrillation, Heart Rate Control
Interventions
Dexmedetomidine Hydrochloride, Normal Saline
Drug · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Gender Dysphoria, Opioid Use, Pain, Postoperative
Interventions
Ropivacaine 0.2% Injectable Solution, Saline (0.9%)
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 2 Interventional Results available

A Study of LY2951742 in Participants With Migraine

NCT01625988
Conditions
Migraine Headache
Interventions
LY2951742, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
37
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 30 more
Conditions
Acute Myocardial Infarction, Congestive Heart Failure, ST-Elevation Myocardial Infarction
Interventions
IK-5001, Saline Solution
Device
Lead sponsor
Bellerophon BCM LLC
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
16
States / cities
Birmingham, Alabama • Torrance, California • Washington D.C., District of Columbia + 13 more
Conditions
Nail Psoriasis
Interventions
Methotrexate, Triamcinolone Acetonide 10mg/mL, Saline
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
SARS-CoV-2 Infection
Interventions
25 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant), Sodium chloride, USP, for injection (0.9% NaCl), 50 µg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant)
Biological · Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Silver Spring, Maryland